Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference
Galectin Therapeutics Inc. (GALT)
Last galectin therapeutics inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.galectintherapeutics.com/investor-relations
Company Research
Source: GlobeNewswire
NORCROSS, Ga., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wainwright 9th Annual MASH Virtual Investor Conference, taking place October 21, 2025. H.C. Wainwright 9th Annual MASH Investor ConferenceCompany presentation: October 21, 2025, at 7:00 AM ETWebcast: hereThe live and archived webcast will also be available on the Events & Presentations page in the investors section of the Company’s website. Additionally, the Galectin management team, including Joel Lewis, Chief Executive Officer, and Khurram Jamil, M.D., Chief Medical Officer, will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright. About Galectin TherapeuticsGalectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chron
Show less
Read more
Impact Snapshot
Event Time:
GALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GALT alerts
High impacting Galectin Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GALT
News
- Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data [Seeking Alpha]Seeking Alpha
- Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Galectin Therapeutics GAAP EPS of -$0.13 [Seeking Alpha]Seeking Alpha
- Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business UpdateGlobeNewswire
- Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual MeetingGlobeNewswire
GALT
Sec Filings
- 12/4/25 - Form 4
- 12/3/25 - Form 8-K
- 11/19/25 - Form 4
- GALT's page on the SEC website